Editorial Staff

First-of-Its-Kind Interactive Mapping Tool Reveals Extent of For-Profit Entities Benefitting from the 340B Drug Pricing Program

/in , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Pioneer Institute Database Spotlights How 340B Covered Entities Utilize Thousands of Out-of-State Contract Pharmacies to Turn Profits in Program Intended to Serve Vulnerable Patients

JANUARY 11, 2023 (BOSTON, MA) – Today, Pioneer Institute released a first-of-its-kind, 50-state mapping tool and database highlighting the troubling way in which hospitals and covered entities leverage unlimited pharmacy contracts under the 340B Drug Pricing Program. Authored by Dr. Bill Smith and Dr. Robert Popovian, the easy-to-use tool and database enables policymakers, legislators, researchers, and practitioners to see the number and location of contract pharmacies for 340B covered entities in all 50 states. Pioneer Institute data visualizations illustrate the growth in the web of for-profit entities now benefitting from the 340B program, a program intended to benefit the most vulnerable patient populations.

The mapping tool features interactive data visualizations that shed light on how 340B entities have taken advantage of the contract pharmacy arrangement, including:

  • Zip code level mapping of the number of contract pharmacies in each state for every 340B covered entity, spotlighting the number of out-of-state pharmacies in high-income areas.
  • State level mapping of contract pharmacy relationships for every 340B covered entity.
  • Growth of contract pharmacy relationships with 340B covered entities since 1992, in all 50 states, including unique contract pharmacies and active contracts with those pharmacies.

“While the 340B program was created with good intentions, evidence continues to show that the program has enormous potential for abuse by for-profit pharmacy chains and pharmacy benefit managers,” said Dr. Bill Smith, Senior Fellow and Director of the Life Sciences Initiative at Pioneer Institute and primary author of the Pioneer tool. “This new tool lays bare how convoluted the 340B program is in design and how for-profit entities are now some of the principal beneficiaries of the program.”

The 340B Drug Pricing Program was established as a federal safety-net program to offer discounts on healthcare treatments to low-income and uninsured populations. In 1996, the Health Resources and Services Administration (HRSA) issued guidance allowing 340B hospitals and other covered entities to dispense 340B drugs through an in-house pharmacy or a single external pharmacy. However, in 2010, HRSA updated its guidance to allow covered entities to contract with an unlimited number of pharmacies to purchase and dispense 340B drugs. As a result, the number of 340B contract pharmacy arrangements has exploded by 4,000% since 2010. As many as 73% of 340B contract pharmacies are large for-profit chains and pharmacy benefit managers.

“The mapping tool clearly demonstrates that powerful hospitals have established tens of thousands of contracts with for-profit entities who are securing enormous profits from the 340B program,” said Dr. Robert Popovian, Senior Visiting Health Policy Fellow at Pioneer Institute and co-author of the Pioneer tool. “There must be increased oversight of 340B covered entities’ use of contract pharmacy relationships to return the program to its original intent of supporting the most vulnerable patients.”

The scope and number of contract pharmacies create an enormous potential for abuse as pharmacies can drive profits by charging multiple discounts, such as purchasing drugs at 340B discounts and billing drug manufacturers for Medicaid rebates on the same drug, known as duplicate discounts. While duplicate discounts violate federal law, and government watchdogs have requested that pharmacies install tools to prevent them, pharmacy chains have not heeded these government requests.

Federal and state legislators and regulators can utilize this new tool to investigate, down to the zip code level, and better grasp how 340B contract pharmacies are taking advantage of the program. Recent research concluded that 340B contract pharmacy growth was concentrated in high-income neighborhoods, compared to low-income communities where the number of contract pharmacies declined.

  • Cambridge Public Health Commission, a Massachusetts-based healthcare system, has 349 contract pharmacies in the state. However, it also has 11 contract pharmacies in California, 11 in Florida, and many more across the country.
  • In Virginia, Bon Secours Richmond Community Hospital, recently the subject of an investigation into their misuse of 340B drug discounts, has a contract pharmacy in Florida and one in Arizona, in addition to contract pharmacies in neighboring states.

To view the Pioneer Institute 340B interactive mapping tool, visit https://pioneerinstitute.org/340babuse/.

###

About the Authors

Dr. William S. Smith is Senior Fellow and Director of the Life Sciences Initiative at Pioneer Institute. He has 25 years of experience in government and in corporate roles, including as vice president of public affairs and policy at Pfizer, and as a consultant to major pharmaceutical, biotechnology and medical device companies. He held senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Massachusetts Governor’s office. He earned his PhD with distinction at The Catholic University of America (CUA).

Dr. Robert Popovian is Senior Visiting Health Policy Fellow at Pioneer Institute. Dr. Popovian is the Founder of the strategic consulting firm Conquest Advisors. He previously served as Vice President, U.S. Government Relations at Pfizer. Dr. Popovian was appointed as the Chief Science Policy Officer for Global Healthy Living Foundation. He also serves on the Board of Councilors of the University of Southern California School of Pharmacy, Senior Health Policy Fellow at Progressive Policy Institute, and Board of Advisors for Equideum Health. Robert completed his Doctorate in Pharmacy and Master of Science in Pharmaceutical Economics and Policy degrees at the University of Southern California with honors.

Gauri Binoy is a research assistant at Pioneer Institute. She graduated from Cornell University with a BA in Biological Sciences and Developmental Sociology in May 2021.

About Pioneer Institute

Pioneer’s mission is to develop and communicate dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond. Pioneer’s vision of success is a state and nation where our people can prosper and our society thrive because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and where our government is limited, accountable and transparent. Pioneer values an America where our citizenry is well-educated and willing to test our beliefs based on facts and the free exchange of ideas, and committed to liberty, personal responsibility, and free enterprise.

Get Updates On Our Life Sciences Work!

Related Content

An “Impending Tsunami” in Mortality from Traditional Diseases?

This report examines whether, after the COVID-19 pandemic subsides, the U.S. will have another looming public health crisis emerging from patients failing to have had their cardiology needs addressed properly during the lockdowns. Moreover, if we surmise that a follow-on public health crisis will emerge, we can also conclude that certain population segments are going to be more impacted by CVD, as there are documented health disparities in this therapeutic area. Finally, there are policy changes that could be taken to mitigate a possible spike in CVD adverse events; the paper will close by recommending certain policy changes.

Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat

Pioneer Institute today released a new analysis focused on cardiovascular disease, An “Impending Tsunami” in Mortality from Traditional Diseases?, that examines how the COVID-19 pandemic has created another unrelated public health crisis. The Pioneer analysis examines how a single-minded public health focus on COVID-19, social distancing, and lockdowns drove reductions in screenings, diagnoses, and early treatment for complex conditions such as heart disease.

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

The QALY and Cancer Treatments: An Ill-Advised Match

This report examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. It reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.

New Analysis: ICER Framework Ignores Patient Preferences, Innovation & Societal Benefits in Evaluating Cost-Effectiveness of New Cancer Treatments

Pioneer Institute today released a new analysis, The QALY and Cancer Treatments: An Ill-Advised Match, that examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. The Pioneer Institute analysis reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.

ICER Proves Its Lack of Business Acumen, Again

0 Comments
/
A recent Institute for Clinical and Economic Review (ICER) “Report on Unsupported Price Increases,” concluded that: “Among the top drugs with price increases in 2019…ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not yet previously known.”  The impression left by the report is that drug companies arbitrarily raise prices without good reason.  As with so many ICER products, the study is misleading and demonstrates a profound lack of business acumen.

Study: Growth of Antibiotic-Resistant Infections Could Have Massive Human, Financial Costs

The world was blindsided by COVID-19, but a new Pioneer Institute study finds that even as we continue to wrestle with the pandemic, another threat looms that scientists have long known about but the nation has thus far failed to address: the growth of antibiotic-resistant infections. “Market dysfunction and perverse Medicare reimbursement rates have led to a growth in infections that resist antibiotics,” said Gunnar Esiason, author of “Antimicrobial Resistance: Learning from the current global health crisis to prevent another one.”  If we don’t solve this problem, the human and economic costs are likely to be astronomical.”

Antimicrobial Resistance: Learning from the current global health crisis to prevent another one

0 Comments
/
The world was blindsided by COVID-19, but a new study finds that…

Study: Growing Drug Rebates Hurt Both Consumers and Healthcare System

Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.

Five Reasons Why Drug Rebates Are Harmful to Patients and to the Healthcare System

Ever-larger rebates are distorting the market for branded drugs and producing outcomes that often benefit neither consumers nor the healthcare system, according to a new study published by Pioneer Institute.